The METTL16–MROH8–TBP–CAPN2 pathway offers potential therapeutic targets for pancreatic cancer treatment, highlighting the significance of m6A modifications in tumor regulation. The gene discussed is METTL16; the disease is familial pancreatic carcinoma.